Program death 1 (PD1) haplotyping in patients with breast carcinoma

Molecular Biology Reports

Volumn 38, Issue 6, 2011, Pages 4205-4210

  Haghshenas, Mohammad Reza ^a   Naeimi, Sirous ^a   Talei, Abdolrasoul ^b   Ghaderi, Abbas ^a,b   Erfani, Nasrollah ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Breast cancer; Haplotype; Immune suppression; Program death 1 (PD 1)

Indexed keywords

PROGRAMMED DEATH 1 RECEPTOR;

ADULT; ANTIGEN PRESENTING CELL; ARTICLE; BREAST CARCINOMA; CANCER INVASION; CANCER STAGING; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC SUSCEPTIBILITY; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; ONCOGENE; PD1 GENE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR VOLUME;

ANTIGENS, CD; APOPTOSIS REGULATORY PROTEINS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 80052430646     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-010-0542-z     Document Type: Article

References (38)

1. Ishida Y et al (1992) Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 11(11):3887-3895.
2. Agata Y et al (1996) Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 8(5):765-772. (Pubitemid 26148299)
3. Freeman GJ et al (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192(7): 1027-1034.
4. Latchman Y et al (2001) PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2(3):261-268. (Pubitemid 33706004)
5. Carter L et al (2002) PD-1: PD-L inhibitory pathway affects both CD4 (+) and CD8 (+) T cells and is overcome by IL-2. Eur J Immunol 32(3):634-643. (Pubitemid 34257540)
6. Mazanet MM, Hughes CC (2002) B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis. J Immunol 169(7):3581-3588.
7. Yamazaki T et al (2002) Expression of programmed death 1 ligands by murine T cells and APC. J Immunol 169(10): 5538-5545. (Pubitemid 35291652)
8. Selenko-Gebauer N et al (2003) B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy. J Immunol 170(7):3637-3644. (Pubitemid 36359233)
9. Ghebeh H et al (2006) The B7-H1 (PD-L1) T lymphocyteinhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 8(3):190-198. (Pubitemid 43671234)
10. Karim R et al (2009) Tumor-expressed B7-H1 and B7-DC in relation to PD-1 + T-cell infiltration and survival of patients with cervical carcinoma. Clin Cancer Res 15(20):6341-6347.
11. Liu SM et al (2008) Expression and significance of B7-H1 and its receptor PD-1 in human gastric carcinoma. Zhonghua Zhong Liu Za Zhi 30(3):192-195.
12. Ohigashi Y et al (2005) Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 11(8):2947-2953. (Pubitemid 40525197)
13. Cao P et al. (2008) Expression and significance of PD-L1 in laryngocarcinoma. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 22 (24):1115-6, 1122.
14. Ghebeh H et al (2008) FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: implication for immunotherapy. BMC Cancer 8:57.
15. Thompson RH et al (2007) PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res 13(6): 1757-1761. (Pubitemid 46952942)
16. Wang W et al (2009) PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4 + CD25 (Hi) regulatory T cells. Int Immunol 21(9):1065-1077.
17. Prokunina L et al (2002) A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet 32(4):666-669. (Pubitemid 35435182)
18. Kroner A et al (2005) A PD-1 polymorphism is associated with disease progression in multiple sclerosis. Ann Neurol 58(1): 50-57. (Pubitemid 40962460)
19. Bertsias GK et al (2009) Genetic, immunologic, and immunohistochemical analysis of the programmed death 1/programmed death ligand 1 pathway in human systemic lupus erythematosus. Arthritis Rheum 60(1):207-218.
20. Lin SC et al (2004) Association of a programmed death 1 gene polymorphism with the development of rheumatoid arthritis, but not systemic lupus erythematosus. Arthritis Rheum 50(3): 770-775.
21. Galea MH et al (1992) The Nottingham prognostic index in primary breast cancer. Breast Cancer Res Treat 22(3):207-219.
22. Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16(3):1215.
23. Excoffier L, Laval G, Schneider S (2005) Arlequin: an integrated software package for population genetics data analysis. Evol Bioinform Online 1:47-50.
24. Mu CY et al (2010) High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol. doi:10.1007/s12032-010-9515- 2.
25. Hino R et al (2010) Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 116(7):1757-1766.
26. Iwai Y et al (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 99(19):12293-12297.
27. Brown JA et al (2003) Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol 170(3):1257-1266. (Pubitemid 36139491)
28. Prokunina L et al (2004) The systemic lupus erythematosus associated PDCD1 polymorphism PD1.3A in lupus nephritis. Arthritis Rheum 50(1):327-328. (Pubitemid 38084318)
29. Prokunina L et al (2004) Association of the PD-1.3A allele of the PDCD1 gene in patients with rheumatoid arthritis negative for rheumatoid factor and the shared epitope. Arthritis Rheum 50(6):1770-1773. (Pubitemid 38725088)
30. Johansson M et al (2005) Association of a PDCD1 polymorphism with renal manifestations in systemic lupus erythematosus. Arthritis Rheum 52(6):1665-1669. (Pubitemid 40852873)
31. Liu JL et al (2009) Association between the PD1.3A/G polymorphism of the PDCD1 gene and systemic lupus erythematosus in European populations: a meta-analysis. J Eur Acad Dermatol Venereol 23(4):425-432.
32. Nielsen C et al (2003) Association of a putative regulatory polymorphism in the PD-1 gene with susceptibility to type 1 diabetes. Tissue Antigens 62(6):492-497. (Pubitemid 37479307)
33. Meng Q et al (2009) PDCD1 genes may protect against extraocular manifestations in Chinese Han patients with Vogt- Koyanagi-Harada syndrome. Mol Vis 15:386-392.
34. Wang SC et al (2006) Programmed death-1 gene polymorphisms in patients with systemic lupus erythematosus in Taiwan. J Clin Immunol 26(6):506-511.
35. Lee SH et al (2006) Association of the programmed cell death 1 (PDCD1) gene polymorphism with ankylosing spondylitis in the Korean population. Arthritis Res Ther 8(6):R163.
36. Liu X et al (2009) Programmed cell death 1 gene polymorphisms is associated with ankylosing spondylitis in Chinese Han population. Rheumatol Int. doi:10.1007/s00296-009-1264-1.
37. Kong EK et al (2005) A new haplotype of PDCD1 is associated with rheumatoid arthritis in Hong Kong Chinese. Arthritis Rheum 52(4):1058-1062. (Pubitemid 40530111)
38. Asad S et al (2007) No evidence of association of the PDCD1 gene with Type 1 diabetes. Diabet Med 24(12):1473-1477.